Atossa Genetics (NASDAQ:ATOS) Issues Earnings Results, Misses Estimates By $0.29 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings results on Wednesday. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.29), FiscalAI reports.

Atossa Genetics Trading Down 1.6%

Shares of NASDAQ:ATOS traded down $0.09 during trading on Wednesday, reaching $5.42. The company’s stock had a trading volume of 129,381 shares, compared to its average volume of 145,913. The stock has a market capitalization of $46.67 million, a PE ratio of -1.51 and a beta of 1.42. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The firm’s 50 day simple moving average is $5.95 and its two-hundred day simple moving average is $10.05.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its stake in shares of Atossa Genetics by 581.2% in the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after purchasing an additional 144,412 shares during the last quarter. &PARTNERS bought a new position in shares of Atossa Genetics during the 4th quarter valued at approximately $25,000. Graham Capital Management L.P. raised its holdings in Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after buying an additional 45,923 shares during the period. State Street Corp raised its holdings in Atossa Genetics by 31.2% during the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after buying an additional 141,990 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after buying an additional 514,175 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Ascendiant Capital Markets raised their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $95.00.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.